相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: A retrospective cohort study
Steven T. Chen et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Hamzah Abu-Sbeih et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
Lauren Julia Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research
Douglas B Johnson et al.
LANCET ONCOLOGY (2020)
Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma
Henry T. Quach et al.
JAMA ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Alice Tison et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Review of cancer treatment with immune checkpoint inhibitors
Christiane Thallinger et al.
WIENER KLINISCHE WOCHENSCHRIFT (2018)
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
Katharina C. Kaehler et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
Francois-Xavier Danlos et al.
EUROPEAN JOURNAL OF CANCER (2018)
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
Koji Haratani et al.
JAMA ONCOLOGY (2018)
Immune Checkpoint Inhibitor Toxicity in 2018
Douglas B. Johnson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review
Marlies De Bock et al.
CASE REPORTS IN DERMATOLOGY (2018)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
Anti-PD1-induced psoriasis: a study of 21 patients
J. Bonigen et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Palmoplantar exacerbation of psoriasis after nivolumab for lung cancer
Tracey N. Liebman et al.
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY (2017)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options
Saad A. Khan et al.
JAMA ONCOLOGY (2016)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Psoriasis prevalence among adults in the United States
Tara D. Rachakonda et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Updated assessment of the prevalence, spectrum and case definition of autoimmune disease
Scott M. Hayter et al.
AUTOIMMUNITY REVIEWS (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Psoriasis 1 - Pathogenesis and clinical features of psoriasis
Christopher E. M. Griffiths et al.
LANCET (2007)
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy
KL Knutson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Psoriasis: epidemiology, clinical features, and quality of life
RGB Langley et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
分享论文
